← TAKEDA PHARMACEUTICAL CO LTD (TAK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
TAKEDA PHARMACEUTICAL CO LTD (TAK)
Pharmaceutical Preparations · market cap $60.2B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Takeda Pharmaceutical (TAK) is a Japanese multinational pharma ranked among the global top 20 by revenue, with ~49,578 employees and a market cap of ~$48.9B at ~$16.96/share. The company operates across oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines, with a dense late-stage pipeline and a series of high-importance catalysts scheduled through mid-2027. Analyst consensus is strong buy with a mean target of ~$20.97, implying ~24% upside from current levels.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-10-31 (est.)Phase 2 · TAK-788imp 7/10
- 2026-11-10PDUFA · TAK-771imp 9/10
- 2026-11-30 (est.)Phase 2 · TAK-360imp 7/10
- 2027-02-10 (est.)Phase 3 · Teduglutideimp 9/10
- 2027-03-16 (est.)Phase 3 · TAK-755imp 9/10
- 2027-05-18 (est.)Phase 3 · Active Comparatorimp 9/10
- 2027-05-18 (est.)Phase 3 · Zasocitinibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| REPLAGAL | Phase 3 | Fabry Disease |
| IGSC 20% infusion | Phase 3 | Primary Immunodeficiency Disease |
| Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus |
| HYQVIA | Phase 3 | Primary Immunodeficiency Diseases (PID) |
| Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Phase 2 | Dengue Fever |
| Leuprorelin acetate | Phase 2 | Endometriosis |
| Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. | Phase 3 | Hypertension |
| Lapaquistat acetate and atorvastatin | Phase 3 | Hypercholesterolemia |
| Glyburide | Phase 3 | Diabetes Mellitus |
| Lapaquistat acetate and additional lipid-lowering therapy | Phase 3 | Hypercholesterolemia |
| Vedolizumab | Phase 3 | Colitis, Ulcerative |
| TAK-861 | Phase 3 | Narcolepsy Type 1 |
| Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension |
| Zasocitinib (Dose A) | Phase 2 | Hidradenitis Suppurativa |
| Norwalk VLP vaccine | Phase 2 | Acute Gastroenteritis |
| Glipizide | Phase 3 | Diabetes Mellitus |
| Vortioxetine | Phase 3 | Major Depressive Disorder |
| TAK-881 | Phase 3 | Primary Immunodeficiency Diseases (PID) |
| TAK-536 | Phase 3 | Hypertension |
| NoV Vaccine | Phase 2 | Healthy Volunteers |
Price & technical context
3-month
+6.5%
6-month
-4.8%
12-month
+21.2%
52-wk range
$13.23–$19.05
vs 50-day MA
-0.8%
vs 200-day MA
+4.1%
Realized vol
23.4%
Max drawdown
-20.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TAK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.